UY37897A - ARNi VARIANTE - Google Patents
ARNi VARIANTEInfo
- Publication number
- UY37897A UY37897A UY0001037897A UY37897A UY37897A UY 37897 A UY37897 A UY 37897A UY 0001037897 A UY0001037897 A UY 0001037897A UY 37897 A UY37897 A UY 37897A UY 37897 A UY37897 A UY 37897A
- Authority
- UY
- Uruguay
- Prior art keywords
- recombinant
- rnai
- arni
- variante
- disease
- Prior art date
Links
- 241000320892 Clerodendrum phlomidis Species 0.000 title 1
- 108091030071 RNAI Proteins 0.000 abstract 3
- 230000009368 gene silencing by RNA Effects 0.000 abstract 3
- 208000023105 Huntington disease Diseases 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013608 rAAV vector Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente memoria se proporcionan moléculas de ARNi para tratar la enfermedad de Huntington. En la presente memoria se proporcionan adicionalmente casetes de expresión, vectores (p.ej., vectores de rAAV, adenovirales recombinantes, lentivirales recombinantes, y de HSV recombinantes), células, partículas virales, y composiciones farmacéuticas que contienen el ARNi. En la presente memoria se proporcionan también adicionalmente métodos y kits relacionados con el uso del ARNi, p.ej., para tratar la enfermedad de Huntington.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762561843P | 2017-09-22 | 2017-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37897A true UY37897A (es) | 2019-04-30 |
Family
ID=64017428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037897A UY37897A (es) | 2017-09-22 | 2018-09-21 | ARNi VARIANTE |
Country Status (17)
Country | Link |
---|---|
US (2) | US11603529B2 (es) |
EP (1) | EP3684932A1 (es) |
JP (1) | JP7248658B2 (es) |
CN (1) | CN111356763B (es) |
AR (1) | AR113134A1 (es) |
AU (1) | AU2018335410A1 (es) |
BR (1) | BR112020005569A2 (es) |
CA (1) | CA3076191A1 (es) |
CO (1) | CO2020003187A2 (es) |
IL (1) | IL273394A (es) |
MX (1) | MX2020003095A (es) |
PH (1) | PH12020550117A1 (es) |
SG (1) | SG11202002488UA (es) |
TW (1) | TW201923079A (es) |
UY (1) | UY37897A (es) |
WO (1) | WO2019060726A1 (es) |
ZA (1) | ZA202001586B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3256588A2 (en) | 2015-02-10 | 2017-12-20 | Genzyme Corporation | VARIANT RNAi |
SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
CA3076191A1 (en) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant rnai |
CN112980837B (zh) * | 2019-12-13 | 2023-07-04 | 深圳艾码生物科技有限公司 | 一种抑制HTT基因表达的siRNA及其前体和应用 |
WO2022206819A1 (zh) * | 2021-03-30 | 2022-10-06 | 南京大学 | 一种用于治疗亨廷顿病的rna递送系统 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
JP4860886B2 (ja) | 2000-06-01 | 2012-01-25 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 二本鎖パルボウイルスベクター |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
NZ600121A (en) | 2001-11-13 | 2013-12-20 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
JP2004101787A (ja) | 2002-09-09 | 2004-04-02 | Fuji Xerox Co Ltd | 画像形成装置及び現像装置 |
CA2881743A1 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
AU2006210973A1 (en) * | 2005-01-31 | 2006-08-10 | University Of Iowa Research Foundation | Nucleic acid silencing of Huntington's Disease gene |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
US8173614B2 (en) * | 2007-01-03 | 2012-05-08 | Medtronic, Inc. | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof |
US20090036395A1 (en) | 2007-04-26 | 2009-02-05 | Davidson Beverly L | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
ES2549122T3 (es) | 2007-05-31 | 2015-10-23 | University Of Iowa Research Foundation | Reducción de toxicidad por interferencia de ARN desviada de su diana |
WO2009098196A2 (en) | 2008-02-04 | 2009-08-13 | Biofocus Dpi B.V. | Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases. |
WO2009100502A1 (en) | 2008-02-14 | 2009-08-20 | Monash University | Immunostimulatory sirna molecules |
FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
US8796238B2 (en) | 2009-09-17 | 2014-08-05 | Sigma-Aldrich Co. Llc | Short RNA mimetics |
CA3049237C (en) | 2010-04-23 | 2024-06-11 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
CN103502458B (zh) | 2011-02-17 | 2016-11-16 | 宾夕法尼亚大学托管会 | 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法 |
JP6490426B2 (ja) * | 2012-02-29 | 2019-03-27 | サンガモ セラピューティクス, インコーポレイテッド | ハンチントン病を治療するための方法および組成物 |
CN103224556B (zh) * | 2013-01-31 | 2015-04-15 | 清华大学 | 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用 |
US9550989B2 (en) | 2013-10-03 | 2017-01-24 | Washington University | Rational design of microRNA-siRNA chimeras for multi-functional target suppression |
EP3068905A4 (en) * | 2013-11-11 | 2017-07-05 | Sangamo BioSciences, Inc. | Methods and compositions for treating huntington's disease |
UA120050C2 (uk) * | 2014-03-21 | 2019-09-25 | Джензайм Корпорейшн | Генна терапія для лікування пігментного ретиніту |
PT3137497T (pt) | 2014-05-02 | 2021-07-12 | Genzyme Corp | Vetores de aav para terapia genética na retina e snc |
EP3146051B8 (en) * | 2014-05-20 | 2019-11-27 | University of Iowa Research Foundation | Huntington's disease therapeutic compounds |
LT3237618T (lt) * | 2014-12-24 | 2019-07-10 | Uniqure Ip B.V. | Rnri sukeltas hantingtino geno slopinimas |
EP3256588A2 (en) * | 2015-02-10 | 2017-12-20 | Genzyme Corporation | VARIANT RNAi |
SG11201809643UA (en) * | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
CA3076191A1 (en) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant rnai |
BR112021001980A2 (pt) * | 2018-08-03 | 2021-05-04 | Genzyme Corporation | rnai variante contra alfa-sinucleína |
-
2018
- 2018-09-21 CA CA3076191A patent/CA3076191A1/en active Pending
- 2018-09-21 WO PCT/US2018/052221 patent/WO2019060726A1/en unknown
- 2018-09-21 SG SG11202002488UA patent/SG11202002488UA/en unknown
- 2018-09-21 MX MX2020003095A patent/MX2020003095A/es unknown
- 2018-09-21 EP EP18793503.6A patent/EP3684932A1/en active Pending
- 2018-09-21 JP JP2020516666A patent/JP7248658B2/ja active Active
- 2018-09-21 BR BR112020005569-7A patent/BR112020005569A2/pt unknown
- 2018-09-21 CN CN201880073881.6A patent/CN111356763B/zh active Active
- 2018-09-21 UY UY0001037897A patent/UY37897A/es not_active Application Discontinuation
- 2018-09-21 US US16/649,042 patent/US11603529B2/en active Active
- 2018-09-21 AU AU2018335410A patent/AU2018335410A1/en active Pending
- 2018-09-21 AR ARP180102723A patent/AR113134A1/es unknown
- 2018-09-25 TW TW107133661A patent/TW201923079A/zh unknown
-
2020
- 2020-03-13 ZA ZA2020/01586A patent/ZA202001586B/en unknown
- 2020-03-16 PH PH12020550117A patent/PH12020550117A1/en unknown
- 2020-03-18 IL IL273394A patent/IL273394A/en unknown
- 2020-03-18 CO CONC2020/0003187A patent/CO2020003187A2/es unknown
-
2023
- 2023-02-15 US US18/169,779 patent/US20230392149A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201923079A (zh) | 2019-06-16 |
SG11202002488UA (en) | 2020-04-29 |
CN111356763B (zh) | 2024-03-12 |
EP3684932A1 (en) | 2020-07-29 |
WO2019060726A1 (en) | 2019-03-28 |
US20200216848A1 (en) | 2020-07-09 |
RU2020114229A (ru) | 2021-10-22 |
ZA202001586B (en) | 2024-01-31 |
AR113134A1 (es) | 2020-01-29 |
BR112020005569A2 (pt) | 2020-10-06 |
AU2018335410A1 (en) | 2020-05-07 |
JP2020535803A (ja) | 2020-12-10 |
CN111356763A (zh) | 2020-06-30 |
CA3076191A1 (en) | 2019-03-28 |
MX2020003095A (es) | 2020-10-15 |
US20230392149A1 (en) | 2023-12-07 |
IL273394A (en) | 2020-05-31 |
RU2020114229A3 (es) | 2022-02-01 |
US11603529B2 (en) | 2023-03-14 |
CO2020003187A2 (es) | 2020-04-13 |
PH12020550117A1 (en) | 2020-12-07 |
JP7248658B2 (ja) | 2023-03-29 |
KR20200056428A (ko) | 2020-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37897A (es) | ARNi VARIANTE | |
CL2017002027A1 (es) | Arni variante. | |
CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
BR112019000327A8 (pt) | Anticorpo para anticlaudina 18a2 e uso do mesmo | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2022001719A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
CL2019002473A1 (es) | Composiciones útiles para el tratamiento de atrofia muscular espinal. | |
AR108683A1 (es) | Vectores aav recombinantes que expresan genes osteoprotectores que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamíferos | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
AR113490A1 (es) | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS | |
BR112019004353A2 (pt) | métodos e vetores para tratar distúrbios do cns | |
CO2021002637A2 (es) | Arni variante frente a alfa-sinucleína | |
CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
BR112018017077A2 (pt) | terapias de combinação para tratamento de atrofia muscular espinhal | |
UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
CO2020010793A2 (es) | Composiciones de virus adeno-asociado para restaurar la función del gen pah y métodos de uso de las mismas | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
CO2021003136A2 (es) | Terapias de combinación | |
BR112015016780A2 (pt) | Peptídios | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
AR120048A1 (es) | Uso de virus oncolíticos para el tratamiento del cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231114 |